Edited by: Thomas Bieber
Type III hereditary angio-oedema: clinical and biological features in a French cohort
Article first published online: 7 APR 2010
© 2010 John Wiley & Sons A/S
Volume 65, Issue 10, pages 1331–1336, October 2010
How to Cite
Vitrat-Hincky, V., Gompel, A., Dumestre-Perard, C., Boccon-Gibod, I., Drouet, C., Cesbron, J. Y., Lunardi, J., Massot, C. and Bouillet, L. (2010), Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy, 65: 1331–1336. doi: 10.1111/j.1398-9995.2010.02368.x
- Issue published online: 7 SEP 2010
- Article first published online: 7 APR 2010
- Accepted for publication 15 February 2010
To cite this article: Vitrat-Hincky V, Gompel A, Dumestre-Perard C, Boccon-Gibod I, Drouet C, Cesbron JY, Lunardi J, Massot C, Bouillet L. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy 2010; 65: 1331–1336.
Background: Hereditary angio-oedema (HAE) has been associated with C1inhibitor deficiency. The first cases of type III HAE were described in patients with normal C1Inh antigenic protein level and function and normal C4 levels in 2000. This finding has been reported mostly in women with a family history and may be influenced by exogenous oestrogen exposure.
Objectives: The purpose of this article is to describe the clinical, biological and genetic characteristics of a French population suffering from type III HAE.
Patients and Methods: We conducted a retrospective analysis of angio-oedema (AE) cases seen in the National Reference Centre of AE between 2000 and 2009.
Results: We found 26 patients (from 15 unrelated families) with type III HAE. All but four were women and presented with typical AE attacks, exacerbated by pregnancy or oral contraceptives containing oestrogens (OC). We also found that 54.5% of women were worsened with oestrogen and 23% were oestrogen dependent. All patients improved on long-term prophylactic tranexamic acid treatment; some acute attacks improved with C1Inh concentrate infusion. All of the patients had normal C1Inh and C4 levels. C1Inh function was also normal, except in women receiving OC or during a pregnancy: transient, moderately low levels (32–74% of the normal range) were found in 18 patients tested (67%). No SERPING1 gene mutation was found. Six patients from three unrelated families were heterozygous for an F12 gene variant.
Conclusion: Diagnosis of type III HAE should be based on clinical (typical attacks, often hormonally influenced), laboratory (normal C1Inh antigenic protein) and genetic (F12 gene mutation) evidence.